Targeting a

Fuller Life

Rain Therapeutics researches, develops and translates innovative targeted cancer therapies for patients

Rain Therapeutics is focused on patients struggling with difficult cancers, and we help provide them hope to get their lives back.

Scientific programs

Rain’s programs  target oncogenic drivers for which it is able to genetically select patients it believes will most likely benefit.

MilademetaN

Rain’s lead drug candidate, milademetan, is an oral small molecule, inhibitor of mouse double minute 2 (MDM2). It is in clinical development  in patients with liposarcoma and other MDM2 - dependent cancers.

Rad52 Research program

Rain’s RAD52 research program is currently in preclinical development. RAD52 plays a central role in the DNA Damage Response (DDR) pathway.

Resources & Publications

Rain in the News

Rain Therapeutics to Participate in Citi’s 17th Annual BioPharma Conference
August 31, 2022 8:00 AM
NEWARK, Calif., August 31, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced that company management will be participating in Citi’s 17th Annual BioPharma Conference on September 7-8, 2022 taking place at the Four Seasons Hotel in Boston, MA. Company management will participate in one-on-one investor meetings, and Avanish Vellanki, CEO, will be participating in a company panel for targeted oncology on Thursday, September 8 at 2:40-3:25 PM ET.
Rain Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Recent Progress
August 4, 2022 4:05 PM
NEWARK, Calif., August 4, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (Rain), a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today reported financial results for the second quarter and six months ended June 30, 2022, along with an update on the Company’s key developments, business operations and upcoming milestones.
Rain Therapeutics Announces Completion of Enrollment in Phase 3 MANTRA Trial for Milademetan in Liposarcoma
August 4, 2022 8:00 AM
NEWARK, Calif., August 4, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (Rain), a late-stage biotechnology company developing precision oncology therapeutics, today announced completion of enrollment in its Phase 3 MANTRA randomized, global, registrational trial of its lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53. The trial targeted an enrollment of 160 patients and completed enrollment five months ahead of schedule with 175 patients.